A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis
收藏Figshare2016-01-15 更新2026-04-29 收录
下载链接：
https://figshare.com/articles/dataset/_A_Randomized_Placebo_Controlled_Study_of_SRT2104_a_SIRT1_Activator_in_Patients_with_Moderate_to_Severe_Psoriasis_/1598745
下载链接
链接失效反馈官方服务：
资源简介：
Activation of Sirtuin (silent mating type information regulation 2 homolog) 1, or SIRT1, is an unexplored therapeutic approach for treatment of inflammatory diseases. We randomized 40 patients with moderate-to-severe psoriasis (4:1) to three escalating doses of SRT2104, a selective activator of SIRT1, or placebo. Across all SRT2104 groups, 35% of patients (pTrial RegistrationClinicaltrials.gov NCT01154101
创建时间：
2016-01-15
